Meeder Asset Management Inc. Acquires 5,010 Shares of Amgen, Inc. (AMGN)

Meeder Asset Management Inc. grew its holdings in Amgen, Inc. (NASDAQ:AMGN) by 12.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,387 shares of the medical research company’s stock after buying an additional 5,010 shares during the period. Meeder Asset Management Inc.’s holdings in Amgen were worth $9,617,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. LSV Asset Management increased its position in Amgen by 3.2% during the second quarter. LSV Asset Management now owns 4,157,649 shares of the medical research company’s stock worth $767,460,000 after purchasing an additional 128,865 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Amgen by 2.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock worth $592,025,000 after purchasing an additional 72,205 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Amgen by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock worth $436,551,000 after purchasing an additional 343,690 shares during the last quarter. Bank of Montreal Can increased its position in Amgen by 13.4% during the third quarter. Bank of Montreal Can now owns 2,328,857 shares of the medical research company’s stock worth $482,749,000 after purchasing an additional 275,469 shares during the last quarter. Finally, Swiss National Bank increased its position in Amgen by 3.2% during the second quarter. Swiss National Bank now owns 2,227,926 shares of the medical research company’s stock worth $411,253,000 after purchasing an additional 69,500 shares during the last quarter. Institutional investors and hedge funds own 82.37% of the company’s stock.

Shares of AMGN stock opened at $193.16 on Friday. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05. The stock has a market cap of $125.93 billion, a price-to-earnings ratio of 15.35, a P/E/G ratio of 2.05 and a beta of 1.37. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $210.19.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company had revenue of $5.90 billion during the quarter, compared to analyst estimates of $5.78 billion. During the same quarter last year, the firm posted $3.27 earnings per share. Amgen’s revenue was up 2.3% compared to the same quarter last year. Equities research analysts anticipate that Amgen, Inc. will post 14.24 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 2.73%. The ex-dividend date is Thursday, November 15th. Amgen’s payout ratio is 41.97%.

Several equities research analysts recently issued reports on the stock. Royal Bank of Canada restated a “neutral” rating on shares of Amgen in a research report on Thursday, November 1st. Citigroup raised their price objective on shares of Amgen from $200.00 to $204.00 and gave the stock a “neutral” rating in a research report on Thursday, November 1st. Goldman Sachs Group restated a “buy” rating and set a $221.00 price objective on shares of Amgen in a research report on Wednesday, October 31st. Morgan Stanley raised their price objective on shares of Amgen from $212.00 to $213.00 and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Finally, Oppenheimer set a $224.00 target price on shares of Amgen and gave the stock a “buy” rating in a research note on Tuesday, October 30th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the stock. Amgen presently has a consensus rating of “Hold” and an average target price of $204.55.

TRADEMARK VIOLATION WARNING: “Meeder Asset Management Inc. Acquires 5,010 Shares of Amgen, Inc. (AMGN)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/11/10/meeder-asset-management-inc-acquires-5010-shares-of-amgen-inc-amgn.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Article: Day Trading

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply